Mission Bio announced on Dec. 13, 2018 that it has received $30 million in Series B funding from investors that include Agilent Technologies, Cota, and LAM Capital, to develop its Tapestri platform, which was first introduced in 2017. The company, a spinoff of the University of California (San FOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.